Entity

Time filter

Source Type

Nishi-Tokyo-shi, Japan

Kanai T.,Keio University | Mikami Y.,Keio University | Hayashi A.,Keio University | Hayashi A.,Miyarisan Pharmaceutical Co.
Journal of Gastroenterology | Year: 2015

Intestinal immune homeostasis is regulated by gut microbiota, including beneficial and pathogenic microorganisms. Imbalance in gut bacterial constituents provokes host proinflammatory responses causing diseases such as inflammatory bowel disease (IBD). The development of next-generation sequencing technology allows the identification of microbiota alterations in IBD. Several studies have shown reduced diversity in the gut microbiota of patients with IBD. Advances in gnotobiotic technology have made possible analysis of the role of specific bacterial strains in immune cells in the intestine. Using these techniques, we have shown that Clostridium butyricum as a probiotic induces interleukin-10-producing macrophages in inflamed mucosa via the Toll-like receptor 2/myeloid differentiation primary response gene 88 pathway to prevent acute experimental colitis. In this review, we focus on the new approaches for the role of specific bacterial strains in immunological responses, as well as the potential of bacterial therapy for IBD treatments. © 2015, Springer Japan.


Ohtani K.,Miyarisan Pharmaceutical Co. | Ohtani K.,Kanazawa University | Shimizu T.,Kanazawa University
Toxins | Year: 2016

The Gram-positive anaerobic bacterium Clostridium perfringens is widely distributed in nature, especially in soil and the gastrointestinal tracts of humans and animals. C. perfringens causes gas gangrene and food poisoning, and it produces extracellular enzymes and toxins that are thought to act synergistically and contribute to its pathogenesis. A complicated regulatory network of toxin genes has been reported that includes a two-component system for regulatory RNA and cell-cell communication. It is necessary to clarify the global regulatory system of these genes in order to understand and treat the virulence of C. perfringens. We summarize the existing knowledge about the regulatory mechanisms here. © 2016 by the authors; licensee MDPI, Basel, Switzerland.


Trademark
Miyarisan Pharmaceutical Co. | Date: 2013-12-02

Preparations and cultures of microorganisms as food ingredients other than for medical and veterinary use. Pharmaceutical preparations; nutritional supplements; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; food for babies; dietary supplements for animals; preparations and cultures of microorganisms as food ingredients for medical and veterinary use; all aforementioned goods except of for the treatment of diseases and complaints of the teeth, the oral cavity, the pharynx and the lips. Animal foodstuffs; animal fattening preparations.


Trademark
Miyarisan Pharmaceutical Co. | Date: 2013-12-02

Preparations and cultures of microorganisms as food ingredients other than for medical and veterinary use. Pharmaceutical preparations; nutritional supplements; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; food for babies; dietary supplements for animals; preparations and cultures of microorganisms as food ingredients for medical and veterinary use; all aforementioned goods except of for the treatment of diseases and complaints of the teeth, the oral cavity, the pharynx and the lips. Animal foodstuffs; animal fattening preparations.


Trademark
Miyarisan Pharmaceutical Co. | Date: 2015-07-15

Dietary supplements for animals not for use in treating teeth, the oral cavity, the pharynx, and the lips; non-medicated additives for animal feed for use as nutritional supplements; nutritional supplements not for use in treating teeth, the oral cavity, the pharynx, and the lips; dietary supplements adapted for medical purposes not for use in treating teeth, the oral cavity, the pharynx, and the lips; Pharmaceutical preparations, namely, antiflatulants not for use in treating teeth, the oral cavity, the pharynx, and the lips; pharmaceutical preparation for treatment and prevention of gastrointestinal diseases, namely, irritable bowel syndrome, inflammatory bowel diseases, antibiotic associated diarrhea, infectious diarrhea, constipation, acute and chronic diarrhea, and soft stool; cultures of microorganisms for medical and veterinary use; bacteriological preparations for medical and veterinary use; bacteriological culture mediums; food for babies not for use in treating teeth, the oral cavity, the pharynx, and the lips. Animal foodstuffs; animal fattening preparations not for medical purposes, namely, fodder.

Discover hidden collaborations